Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma
Clinical trial NCT00440635 · COMPLETED
Trial details
- NCT number
- NCT00440635
- Sponsor
- Janssen-Cilag International NV
- Status
- COMPLETED
- Study type
- OBSERVATIONAL
- Start date
- 2004-01-01
- Enrollment
- 641
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.